LONDON, Jan. 17, 2022 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma), the multinational pharmaceutical
company, today announces that it has agreed to acquire the Canadian
assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be
completed before the end of the first quarter of 2022.
The acquisition marks Hikma's expansion into Canada and includes a portfolio of 25 sterile
injectable products, three in-licenced ophthalmic products and a
pipeline of seven additional products, four of which are approved
by Health Canada.
Riad Mishlawi, President of Hikma Injectables, commented, "This
acquisition further expands our portfolio of essential sterile
injectable medicines and gives Hikma an entry into the highly
attractive Canadian injectables market. The combination of our
sales and marketing expertise and this portfolio of exciting
products will enable us to expand our North American business and
develop a solid position in this important market."
In October 2021,
Teligent filed for voluntary protection under Chapter 11 of
the U.S. Bankruptcy Code. As part of this process, Teligent
initiated a sale of its core assets, following which Hikma has
agreed to acquire Teligent's Canadian assets.
Enquiries:
|
|
|
|
Hikma
(Investors):
|
|
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/
+44 (0)7776 477050
|
Guy
Featherstone
Senior Investor
Relations
Manager
|
+44 (0)20 3892 4389/
+44 (0)7795 896738
|
Layan
Kalisse
Investor Relations
Analyst
|
+44 (0)20 7399 2788/
+44 (0)7970 709912
|
|
|
Teneo
(Press):
|
|
Charles
Armitstead
|
+44 (0)7703 330
269
|
|
|
US
Media
|
|
Steven Weiss/David
Belian
|
+1 732 788 8279/ +1
848 254 4875
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch) Hikma
helps put better health within reach every day for millions of
people around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the
people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hikma-expands-into-canada-with-acquisition-of-teligent-sterile-injectable-assets-301461781.html
SOURCE Hikma Pharmaceuticals USA Inc.